Naringenin Mitigates Dasatinib-Induced Kidney Damage by Modulating Antioxidant Defense, Inflammation, and Apoptosis

Khalid Alhazzani1, Naif N Alqarni1, Khaldoon Aljerian2

  • 1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Insights

Naringenin (NGN) protects against dasatinib (DASA)-induced kidney injury by reducing oxidative stress, inflammation, and apoptosis. This study highlights NGN

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Background:

  • Tyrosine kinase inhibitors like dasatinib (DASA) can cause significant nephrotoxicity.
  • Naringenin (NGN) possesses known antioxidant and anti-inflammatory properties.
  • Understanding protective mechanisms against drug-induced kidney injury is crucial.

Purpose of the Study:

  • To investigate the nephroprotective effects of naringenin (NGN) against dasatinib (DASA)-induced acute kidney injury.
  • To evaluate the impact of NGN on oxidative stress, inflammation, and apoptosis markers in a mouse model.

Main Methods:

  • Mice were pre-treated with varying doses of NGN (50, 100 mg/kg) for one week.
  • Acute kidney injury was induced by a single dose of DASA (25 mg/kg) on day 8.
  • Serum markers (BUN, creatinine, LDH, uric acid), kidney tissue MDA, GSH, CAT, and gene expression (TNF-α, NF-κB, IL-6, BAX, BCL-2, Caspase-3) were analyzed.

Main Results:

  • NGN pretreatment significantly attenuated DASA-induced increases in serum BUN, creatinine, uric acid, and LDH.
  • NGN reduced elevated malondialdehyde (MDA) levels and restored glutathione (GSH) and catalase (CAT) levels in kidney tissues.
  • NGN mitigated DASA-induced upregulation of pro-inflammatory cytokines (TNF-α, NF-κB, IL-6) and modulated apoptotic gene expression (BAX, BCL-2, Caspase-3).

Conclusions:

  • Naringenin (NGN) demonstrates significant nephroprotective potential against dasatinib (DASA)-induced acute kidney injury in mice.
  • NGN exerts its protective effects via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms.
  • Further research is needed to fully elucidate the molecular pathways involved in NGN's nephroprotective action.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
437
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
34
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
131
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
373
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273